Evidence map›Paper›PMID 39436411›Full record

ArticleEuropean radiology2025

Prognostic value of interim [

Eonwoo Shin, Yong-Il Kim, Changhoon Yoo, Yeokyeong Shin, Baek-Yeol Ryoo, Dong Yun Lee, Jin-Sook Ryu

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Eonwoo ShinDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yong-Il Kim *Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. kyi821209@naver.com.ORCID http://orcid.org/0000-0002-4113-8351
Changhoon Yoo *Theranostics Center, Asan Cancer Institute, Asan Medical Center, Seoul, Republic of Korea. yooc@amc.seoul.kr.
Yeokyeong ShinDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Baek-Yeol RyooTheranostics Center, Asan Cancer Institute, Asan Medical Center, Seoul, Republic of Korea.
Dong Yun LeeDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jin-Sook RyuDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Funding

Ministry of Health and Welfare HR18C0016
6 · The paper itself

Abstract

objectivesThis study evaluated the prognostic value of basal and interim [

methodsPatients with NET who received PRRT with [

resultsTwenty-four patients were finally included (10 men and 14 women, median age of 56.5 years, age range 32-74 years). Among them, 16 patients (66.7%) experienced disease progression. In univariate analysis, high ∆WTV (≥ -10%, hazard ratio [HR] = 3.053 [1.003-9.289], p = 0.049) and high ∆TRE (≥ -21%, HR = 3.567 [1.144-11.122], p = 0.028) were significantly associated with shorter PFS. In multivariate analyses adjusted for WHO grade, high ∆WTV (HR = 3.345 [1.055-10.601], p = 0.043) and high ∆TRE (HR = 3.894 [1.194-12.695], p = 0.024) were significant predictors of shorter PFS.

conclusionThe study demonstrates that basal and interim [ KEY POINTS: Question Peptide receptor radionuclide therapy is utilised for patients with somatostatin receptor-positive well-differentiated neuroendocrine tumours; however, prognostic predictors are not well established. Findings Progression-free survival was significantly associated with the proportional change in whole tumour volume and total receptor expression between basal and interim [

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsPositron Emission Tomography Computed TomographyReceptors, PeptideAdultAgedFemaleGallium RadioisotopesHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesTreatment OutcomeGa(III)-DOTATOCGallium RadioisotopesOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, PeptideNeuroendocrine tumoursPositron emission tomographyPrognosisReceptor (peptide)Receptors (somatostatin)

Identifiers

PMID39436411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.